Renaissance Technologies LLC lifted its position in shares of Transcat, Inc. (NASDAQ:TRNS) by 52.4% in the second quarter, HoldingsChannel.com reports. The firm owned 74,981 shares of the scientific and technical instruments company’s stock after purchasing an additional 25,784 shares during the period. Renaissance Technologies LLC’s holdings in Transcat were worth $1,417,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of TRNS. Dimensional Fund Advisors LP grew its holdings in shares of Transcat by 2.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 316,063 shares of the scientific and technical instruments company’s stock worth $4,946,000 after purchasing an additional 8,621 shares during the period. UBS Group AG lifted its position in Transcat by 62.9% during the 1st quarter. UBS Group AG now owns 66,465 shares of the scientific and technical instruments company’s stock worth $1,040,000 after acquiring an additional 25,664 shares in the last quarter. Dalton Greiner Hartman Maher & Co. lifted its position in Transcat by 42.7% during the 2nd quarter. Dalton Greiner Hartman Maher & Co. now owns 315,932 shares of the scientific and technical instruments company’s stock worth $5,971,000 after acquiring an additional 94,480 shares in the last quarter. Acadian Asset Management LLC lifted its position in Transcat by 491.7% during the 2nd quarter. Acadian Asset Management LLC now owns 18,485 shares of the scientific and technical instruments company’s stock worth $350,000 after acquiring an additional 15,361 shares in the last quarter. Finally, Algert Global LLC acquired a new position in Transcat during the 2nd quarter worth approximately $375,000. Institutional investors and hedge funds own 54.77% of the company’s stock.
Several research firms recently commented on TRNS. Zacks Investment Research raised Transcat from a “hold” rating to a “strong-buy” rating and set a $24.00 price target on the stock in a research report on Tuesday. Singular Research boosted their price target on Transcat from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, August 21st.
Transcat (NASDAQ:TRNS) last released its quarterly earnings results on Wednesday, October 24th. The scientific and technical instruments company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.16 by $0.04. The firm had revenue of $38.88 million for the quarter, compared to analyst estimates of $38.00 million. Transcat had a return on equity of 12.69% and a net margin of 4.54%. Sell-side analysts expect that Transcat, Inc. will post 1 EPS for the current year.
In related news, Director John T. Smith sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 31st. The stock was sold at an average price of $10.30, for a total transaction of $30,900.00. Following the transaction, the director now directly owns 42,166 shares of the company’s stock, valued at approximately $434,309.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 10,639 shares of company stock worth $109,307 over the last three months. 8.80% of the stock is currently owned by corporate insiders.
Transcat Company Profile
Transcat, Inc provides calibration and laboratory instrument services in North America and internationally. It operates in two segments, Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.
See Also: Why do earnings reports matter?
Want to see what other hedge funds are holding TRNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Transcat, Inc. (NASDAQ:TRNS).
Receive News & Ratings for Transcat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transcat and related companies with MarketBeat.com's FREE daily email newsletter.